Difference between revisions of "Stephen Moses"
Jump to navigation
Jump to search
m |
m |
||
| Line 28: | Line 28: | ||
| url= | | url= | ||
| pubmedID=16225538 | | pubmedID=16225538 | ||
| + | | DOI=10.1111/j.1464-410X.2005.05810.x | ||
| accessdate= | | accessdate= | ||
| − | |||
}}</ref> which are being used by the [[World Health Organization]] (under the guide of [[UNAIDS]]) to endorse circumcision as an HIV prevention method.<ref>{{REFweb | }}</ref> which are being used by the [[World Health Organization]] (under the guide of [[UNAIDS]]) to endorse circumcision as an HIV prevention method.<ref>{{REFweb | ||
| last=World Health Organization | | last=World Health Organization | ||
| Line 83: | Line 83: | ||
| pubmedID=19626601 | | pubmedID=19626601 | ||
| pubmedCID=2795021 | | pubmedCID=2795021 | ||
| + | | DOI=10.1002/ijc.24770 | ||
| accessdate= | | accessdate= | ||
| − | |||
}}</ref><br><small>Smith JS, Hudgens MG, '''[[Robert C. Bailey|Bailey RC]]''', Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7.</small> | }}</ref><br><small>Smith JS, Hudgens MG, '''[[Robert C. Bailey|Bailey RC]]''', Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7.</small> | ||
* Top Achievements in Health Research: Male circumcision: a new approach to reducing HIV transmission.<ref>{{REFjournal | * Top Achievements in Health Research: Male circumcision: a new approach to reducing HIV transmission.<ref>{{REFjournal | ||
| Line 99: | Line 99: | ||
| pubmedID=19786481 | | pubmedID=19786481 | ||
| pubmedCID=2761462 | | pubmedCID=2761462 | ||
| + | | DOI=10.1503/cmaj.090809 | ||
| accessdate= | | accessdate= | ||
| − | |||
}}}</ref><br><small>Moses S. CIHR/CMAJ 2009; 181: E134-5.</small> | }}}</ref><br><small>Moses S. CIHR/CMAJ 2009; 181: E134-5.</small> | ||
* Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.<ref>{{REFjournal | * Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.<ref>{{REFjournal | ||
| Line 115: | Line 115: | ||
| pubmedID=19571722 | | pubmedID=19571722 | ||
| pubmedCID=2772053 | | pubmedCID=2772053 | ||
| + | | DOI=10.1097/QAD.0b013e32832afe95 | ||
| accessdate= | | accessdate= | ||
| − | |||
}} | }} | ||
</ref><br><small>Mehta SD, '''[[Ronald Gray|Gray RH]]''', '''[[Bertran Auvert|Auvert B]]''', Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, '''[[Maria Wawer|Wawer MJ]]''', '''[[Robert C. Bailey|Bailey RC]]'''. AIDS 2009; 23: 1557-64.</small> | </ref><br><small>Mehta SD, '''[[Ronald Gray|Gray RH]]''', '''[[Bertran Auvert|Auvert B]]''', Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, '''[[Maria Wawer|Wawer MJ]]''', '''[[Robert C. Bailey|Bailey RC]]'''. AIDS 2009; 23: 1557-64.</small> | ||
| Line 131: | Line 131: | ||
| url= | | url= | ||
| pubmedID=17321310 | | pubmedID=17321310 | ||
| + | | DOI=10.1016/S0140-6736(07)60312-2 | ||
| accessdate= | | accessdate= | ||
| − | |||
}} | }} | ||
</ref><br><small>'''[[Robert C. Bailey|Bailey RC]]''', Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56.</small> | </ref><br><small>'''[[Robert C. Bailey|Bailey RC]]''', Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56.</small> | ||
| Line 148: | Line 148: | ||
| pubmedID=17355625 | | pubmedID=17355625 | ||
| pubmedCID=1832203 | | pubmedCID=1832203 | ||
| + | | DOI=10.1186/1471-2334-7-16 | ||
| accessdate= | | accessdate= | ||
| − | |||
}}</ref><br><small>Nagelkerke NJD, Moses S, de Vlas S, '''[[Robert C. Bailey|Bailey RC]]'''. BMC Infect Dis 2007; 7: 16.</small> | }}</ref><br><small>Nagelkerke NJD, Moses S, de Vlas S, '''[[Robert C. Bailey|Bailey RC]]'''. BMC Infect Dis 2007; 7: 16.</small> | ||
* Adult male circumcision outcomes: experience in a developing country setting.<ref>{{REFjournal | * Adult male circumcision outcomes: experience in a developing country setting.<ref>{{REFjournal | ||
| Line 163: | Line 163: | ||
| pages=235–40 | | pages=235–40 | ||
| pubmedID=17406133 | | pubmedID=17406133 | ||
| + | | DOI=10.1159/000099344 | ||
| accessdate= | | accessdate= | ||
| − | |||
}} | }} | ||
</ref><br><small>Krieger J, '''[[Robert C. Bailey|Bailey RC]]''', Agot K, Parker C, Ndinya-Achola JO, Moses S, et al. Urol Int 2007; 78: 235-40.</small> | </ref><br><small>Krieger J, '''[[Robert C. Bailey|Bailey RC]]''', Agot K, Parker C, Ndinya-Achola JO, Moses S, et al. Urol Int 2007; 78: 235-40.</small> | ||
Revision as of 13:28, 22 August 2019
|
| Associates With: |
| Gilgal Society Circlist |
| Colleagues & Benefactors: |
| Daniel T. Halperin Edgar J. Schoen Robert C. Bailey Bertran Auvert Maria J. Wawer Brian J. Morris |
Professor, Depatrments of Medical Microbiology, Community Health Sciences and Medicine. Stephen Moses has been a circumcision proponent since at least 1994.[1] Moses (along with Robert C. Bailey) was responsible for one of the three major African circumcision trials (funded by NIAID and the Canadian Institutes of Health Research)[2] which are being used by the World Health Organization (under the guide of UNAIDS) to endorse circumcision as an HIV prevention method.[3]
Interests
According to Stephen's bio, his interest is in biological and behavioural risk factors for STI/HIV transmission.[4] Moses has been an advocate of circumcision since at least 1994.[5]
RCT in Kenya
Of the three RCTs being used by the WHO to endorse circumcision as HIV prevention, Stephen Moses and Robert C. Bailey headed the RCT that was carried out in Kenya.[6] All three trials were funded by the American National Institutes of Health.[7]
Active Projects
- A randomized, controlled trial of male circumcision to reduce HIV incidence in Kisumu , Kenya.[4] National Institutes of Health.
- Scaling up HIV prevention in Karnataka and southern Maharashtra , Phase II.[4] Bill & Melinda Gates Foundation.
- Monitoring and evaluation of the Avahan project in India.[4] Bill & Melinda Gates Foundation.
- Technical assistance to improve maternal, neonatal & child health through National Rural Health Mission, India.[4] Bill & Melinda Gates Foundation.
- Mapping key populations for HIV prevention in Sri Lanka.[4] World Bank.
Recent Publications
- Prevalence and risk factors for human papillomavirus infection by penile site in uncircumcised Kenyan men.[8]
Smith JS, Hudgens MG, Bailey RC, Agot K, Ndinya-Achola JO, Moses S, et al. Int J Cancer 2010; 126: 572-7. - Top Achievements in Health Research: Male circumcision: a new approach to reducing HIV transmission.[9]
Moses S. CIHR/CMAJ 2009; 181: E134-5. - Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials.[10]
Mehta SD, Gray RH, Auvert B, Moses S , Kigozi G, Taljaard D, Puren A, Agot K, Serwadda D, Parker CB, Wawer MJ, Bailey RC. AIDS 2009; 23: 1557-64. - Male circumcision for HIV prevention in young men in Kisumu , Kenya: a randomised controlled trial.[11]
Bailey RC, Moses S , Parker CB, Agot K, Maclean I, Krieger JN, et al. Lancet 2007; 369: 643-56. - Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa.[12]
Nagelkerke NJD, Moses S, de Vlas S, Bailey RC. BMC Infect Dis 2007; 7: 16. - Adult male circumcision outcomes: experience in a developing country setting.[13]
Krieger J, Bailey RC, Agot K, Parker C, Ndinya-Achola JO, Moses S, et al. Urol Int 2007; 78: 235-40.
References
- ↑ Moses S., Plummer FA, Bradley, JE, Ndinya-Achola, JO, Nagelkerke NJ, and Ronald AR. The association between lack of male circumcision and risk for HIV infection: a review of the epidemiological data. Sex Transm Dis 1994;21:201-10. 1.
- ↑
Krieger JN, Bailey RC, Opeya J, et al.. Adult male circumcision: results of a standardized procedure in Kisumu District, Kenya. BJU Int.. 96(7): 1109–13. PMID. DOI.
- ↑
World Health Organization (27 March 2007). WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention
. Retrieved 23 February 2011. - ↑ a b c d e f Dr. Moses, Stephen. [<title> parameter missing!, University of Manitoba. Retrieved 23 February 2011.
- ↑ Moses S., Plummer FA, Bradley, JE, Ndinya-Achola, JO, Nagelkerke NJ, and Ronald AR. The association between lack of male circumcision and risk for HIV infection: a review of the epidemiological data. Sex Transm Dis 1994;21:201-10.
- ↑ Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-56. Abstract
- ↑ (2008).
The Use of Male Circumcision to Prevent HIV Infection
, Doctors Opposing Circumcision. Retrieved 5 March 2011.
Quote:...funding from the United States National Institutes of Health to conduct randomized controlled trials (RCTs) in Africa.
- ↑ Smith JS, Backes DM, Hudgens MG, et al.. Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. Int. J. Cancer. 126(2): 572–7. PMID. PMC. DOI.
- ↑ Moses S. Male circumcision: a new approach to reducing HIV transmission. CMAJ. 181(8): E134–5. PMID. PMC. DOI.}
- ↑ Mehta SD, Gray RH, Auvert B, et al.. Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials. AIDS. 23(12): 1557–64. PMID. PMC. DOI.
- ↑ Bailey RC, Moses S, Parker CB, et al.. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 369(9562): 643–56. PMID. DOI.
- ↑ Nagelkerke NJ, Moses S, de Vlas SJ, Bailey RC. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect. Dis.. 7: 16. PMID. PMC. DOI.
- ↑ Krieger JN, Bailey RC, Opeya JC, et al.. Adult male circumcision outcomes: experience in a developing country setting. Urol. Int.. 78(3): 235–40. PMID. DOI.
